List of Excipients in Branded Drug ACETAMINOPHEN IBUPROFEN (NSAID)

Generic Drugs Containing ACETAMINOPHEN IBUPROFEN (NSAID)

Company	Ingredient	NDC	Excipient
Dr Reddy's Labortories Inc	acetaminophen and ibuprofen	75907-260	CARNAUBA WAX
Dr Reddy's Labortories Inc	acetaminophen and ibuprofen	75907-260	CROSCARMELLOSE SODIUM
Dr Reddy's Labortories Inc	acetaminophen and ibuprofen	75907-260	FERROSOFERRIC OXIDE
Dr Reddy's Labortories Inc	acetaminophen and ibuprofen	75907-260	GLYCERYL DIBEHENATE

What are the Most Frequently-Used Excipients in ACETAMINOPHEN IBUPROFEN (NSAID)?

# Of NDCs	Excipient
1	CARNAUBA WAX
1	CROSCARMELLOSE SODIUM
1	FERROSOFERRIC OXIDE
1	GLYCERYL DIBEHENATE

Acetaminophen-Ibuprofen Combination Drug: Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: August 7, 2026

The acetaminophen-ibuprofen combination is a mature oral analgesic opportunity with strong consumer demand, low active-ingredient cost, and substantial formulation flexibility. The principal commercial product in the United States is Advil Dual Action, which combines acetaminophen 250 mg and ibuprofen 125 mg per caplet. The strongest opportunities are differentiated tablets, liquid products, orally disintegrating formats, modified-release systems, and products designed for patients who need lower exposure to either active ingredient.

What is the acetaminophen-ibuprofen combination drug?

Acetaminophen, also called paracetamol, provides analgesic and antipyretic activity. Ibuprofen is a nonsteroidal anti-inflammatory drug, or NSAID, that provides analgesic, antipyretic, and anti-inflammatory activity through cyclooxygenase inhibition.

The combination can provide broader pain coverage than either ingredient alone. It is used for temporary relief of headaches, dental pain, muscular aches, backache, menstrual cramps, minor arthritis pain, and fever, subject to product labeling.

A U.S. commercial product, Advil Dual Action, contains:

Product	Acetaminophen	Ibuprofen	Dosage form	Commercial owner
Advil Dual Action	250 mg	125 mg	Immediate-release caplet	Haleon
Typical proposed ratio	2 parts	1 part	Tablet, caplet, capsule, liquid	Multiple potential sponsors

The fixed-dose combination has a practical formulation advantage: both actives are established, inexpensive, chemically stable pharmaceutical ingredients. The principal technical challenge is controlling tablet size, dissolution, dose uniformity, taste, gastrointestinal tolerability, and chemical stability.

What excipient strategy is best for acetaminophen and ibuprofen tablets?

A bilayer or layered tablet is generally the strongest starting platform for a premium product. Acetaminophen and ibuprofen differ in particle characteristics, dose, solubility behavior, compression performance, and formulation sensitivity. Physical separation can improve manufacturability and reduce incompatibility risk.

Recommended immediate-release excipient architecture

Formulation function	Candidate excipient classes	Commercial rationale
Diluent	Microcrystalline cellulose, silicified microcrystalline cellulose, lactose, mannitol	Controls tablet weight and compression
Binder	Povidone, copovidone, hydroxypropyl cellulose	Improves granule and tablet strength
Disintegrant	Croscarmellose sodium, crospovidone, sodium starch glycolate	Supports rapid disintegration
Lubricant	Magnesium stearate, sodium stearyl fumarate	Improves ejection and manufacturing efficiency
Glidant	Colloidal silicon dioxide	Improves powder flow
Wetting aid	Sodium lauryl sulfate or a nonionic surfactant	Can improve ibuprofen wetting and dissolution
Taste masking	Film coating, polymer barrier coating, ion-exchange or lipid systems	Important for chewable and liquid products
Coating	Hypromellose, polyvinyl alcohol, polyethylene glycol, titanium dioxide where permitted	Improves swallowability, identification, and moisture protection

Ibuprofen is poorly water soluble, while acetaminophen has materially higher aqueous solubility. The formulation should therefore prioritize ibuprofen wetting and dissolution without creating excessive acetaminophen release or tablet friability.

Why a bilayer tablet can create value

A bilayer tablet allows each active ingredient to use a separate excipient system. The ibuprofen layer can include wetting agents, surfactant-assisted granulation, or particle-size control. The acetaminophen layer can use a high-dose direct-compression system with robust disintegration.

This architecture can support:

• Distinct dissolution profiles for the two actives.
• Lower risk of segregation during manufacturing.
• Reduced chemical interaction between active ingredients and excipients.
• More defensible formulation know-how.
• Product line extensions using different dose ratios.

A bilayer product may also support patentable claims directed to layer composition, dissolution limits, manufacturing sequence, compression force, or stability performance. Patentability depends on unexpected technical results and claim drafting, not on the use of a bilayer structure alone.

What formulations are protected or commercially differentiated?

The main formulation opportunity is not a new chemical entity. It is a differentiated delivery system that improves convenience, tolerability, onset, or adherence.

Immediate-release caplets

Immediate-release caplets have the lowest development and regulatory risk. They are suitable for general OTC distribution and private-label competition. The commercial weakness is limited product differentiation because the active ingredients and dose ratio can be copied through an abbreviated or monograph-based pathway, depending on jurisdiction.

Film-coated tablets

Film coating improves swallowability, protects the tablet from moisture, and permits color and brand differentiation. It generally provides weak standalone patent protection but can support trade dress, quality differentiation, and consumer positioning.

Liquids and suspensions

Pediatric or adult liquid products create higher formulation value because ibuprofen and acetaminophen have different solubility and taste profiles. A liquid combination may require:

• Separate dissolution or suspension control.
• Suspending agents such as xanthan gum, microcrystalline cellulose with carboxymethylcellulose, or sodium carboxymethylcellulose.
• Sweeteners and flavor systems.
• Preservative systems.
• pH control.
• Sedimentation and redispersibility testing.
• Child-resistant packaging.

A dual-chamber package or co-packaged liquid system may reduce stability risk by keeping the active ingredients separate until administration. That approach can generate stronger device and packaging claims than a conventional bottle.

Chewable and orally disintegrating products

Chewables and orally disintegrating tablets can improve access for patients who have difficulty swallowing. They create formulation challenges because ibuprofen is bitter, acetaminophen has a high dose burden, and the combined tablet may require substantial taste-masking material.

Mannitol, crospovidone, flavor systems, sweeteners, polymer coatings, and lipid-based taste barriers are potential tools. A successful product may command a higher retail price but requires stronger sensory testing and more complex stability work.

Modified-release products

A modified-release combination could differentiate the product by extending analgesic coverage or separating the release timing of the two ingredients. The development burden is materially higher because the sponsor must establish:

• Release control for both actives.
• Food-effect performance.
• Dose proportionality.
• Consistent pharmacokinetics.
• Clinical relevance of the release profile.
• Safety under prolonged exposure.

Modified-release claims are more commercially defensible than conventional immediate-release claims, but the regulatory and clinical investment is also higher.

What FDA regulatory pathway applies?

The U.S. regulatory route depends on the proposed product, labeling, dosage strength, and whether the sponsor relies on an existing reference product.

OTC pathway

Many acetaminophen and ibuprofen products are regulated under FDA OTC monograph conditions. The sponsor must comply with the applicable monograph requirements, ingredient concentrations, warnings, directions, dosage forms, labeling, and manufacturing controls.

A fixed-dose combination may require an approved NDA if the exact combination is not covered by an OTC monograph or if the sponsor makes claims outside the monograph framework. Advil Dual Action was approved as a prescription-to-OTC-style commercial product under an FDA application pathway rather than relying solely on a broad general analgesic monograph.

NDA or abbreviated pathway

A sponsor may pursue:

• An NDA for a novel combination, delivery system, or labeling concept.
• An ANDA if an approved reference listed drug and suitable product specifications exist.
• A monograph-based OTC product where all conditions are satisfied.
• A 505(b)(2) application for a modified formulation or combination relying partly on existing safety and efficacy information.

The regulatory value of the product increases when the formulation has a clinically meaningful advantage, such as lower dose exposure, faster onset, improved gastrointestinal tolerability, or better adherence.

What is the Orange Book status of acetaminophen-ibuprofen products?

The FDA Orange Book records approved drug products and, where applicable, patent and exclusivity information. The Orange Book status must be assessed at the individual NDA and product level rather than inferred from the active ingredients.

For a mature acetaminophen-ibuprofen combination, the key questions are:

1. Is the reference product listed as an NDA product?
2. Are patents listed for the specific strength, dosage form, formulation, or method of use?
3. Has any listed patent expired or been delisted?
4. Is pediatric exclusivity attached?
5. Is an ANDA pathway available for the proposed product?

The active ingredients themselves are long-established and do not provide meaningful new-molecule exclusivity. Any remaining protection would generally arise from formulation, dosage form, manufacturing, packaging, labeling, or method-of-use claims.

When does acetaminophen-ibuprofen lose exclusivity?

The combination has limited potential for long-term exclusivity based solely on the active ingredients. Acetaminophen and ibuprofen are established generic ingredients, and conventional immediate-release tablets face substantial substitution risk.

The relevant commercial timeline is:

Protection type	Expected position
New chemical entity exclusivity	Not available for established actives
Basic active-ingredient patents	Expired or commercially irrelevant
Conventional tablet formulation	Generally vulnerable to generic competition
Novel formulation patent	Potentially valuable if valid and enforceable
Pediatric exclusivity	Product-specific and time-limited
Trademark and trade dress	Can persist while actively maintained
Regulatory exclusivity for a new delivery system	Depends on approval pathway and product attributes

A sponsor with a novel modified-release, liquid, pediatric, or device-enabled product may obtain a stronger commercial position than a sponsor selling a standard immediate-release tablet.

Which companies are challenging the acetaminophen-ibuprofen market?

The competitive field includes branded manufacturers, private-label suppliers, contract manufacturers, and global generic companies.

Branded competition

Haleon has the strongest U.S. branded position through Advil and Advil Dual Action. Johnson & Johnson Consumer, through Tylenol, controls the leading acetaminophen brand platform. The commercial competition is therefore not limited to fixed-dose combination products. Consumers can also alternate or co-administer single-ingredient products, depending on label instructions and medical advice.

Generic and private-label competition

Retailers and generic manufacturers can compete through:

• Acetaminophen 250 mg and ibuprofen 125 mg combination tablets.
• Different dose ratios.
• Lower-priced bottle sizes.
• Store-brand packaging.
• Club-store multipacks.
• E-commerce bundles.
• Pediatric liquids and chewables.

The principal barriers are regulatory documentation, manufacturing scale, quality control, and retail distribution. The API supply chain is not the central barrier.

What patent litigation and Paragraph IV risks exist?

Paragraph IV risk is generally strongest when a sponsor seeks to copy a marketed product with listed patents directed to a formulation, dosage form, or method of use. For an established acetaminophen-ibuprofen product, the likely litigation triggers are:

• A listed patent covering a specific combination ratio.
• A bilayer or multilayer structure.
• Modified-release release-control technology.
• A liquid suspension or taste-masking system.
• A method-of-use claim covering a defined dosing regimen.
• A device or co-packaged delivery system.

A conventional immediate-release generic may have a lower litigation profile if it does not rely on protected formulation claims. The sponsor must still evaluate Orange Book listings, patent certifications, labeling constraints, and potential induced-infringement theories.

Generic launch scenarios

Scenario	Commercial effect
No enforceable formulation patent	Early generic or private-label entry is possible
Narrow formulation patent remains valid	Design-around products may enter
Broad formulation patent survives litigation	Reference-product pricing may persist
Patent settlement delays entry	Market may remain branded until the agreed date
Competing OTC monograph products launch	Price erosion can occur without patent litigation

No specific current Paragraph IV settlement should be assumed without reviewing the relevant FDA and court records for the exact reference product and jurisdiction.

How strong is the patent estate?

The patent estate for a conventional acetaminophen-ibuprofen tablet is structurally weaker than the estate for a new molecular entity or complex biologic. The active ingredients are old, widely available, and supported by extensive prior art.

Patent strength improves when claims are tied to measurable technical performance, such as:

• A defined dissolution profile.
• Reduced ibuprofen particle size.
• A specific bilayer interface.
• Improved chemical stability.
• A defined impurity threshold.
• A taste-masking barrier with demonstrated sensory results.
• A pharmacokinetic advantage.
• A lower total active dose with equivalent analgesic efficacy.
• A specific manufacturing process that produces a reproducible product.

Weak claims include broad combinations of known actives with routine excipients, generic tablet claims, and unsupported assertions of improved dissolution or tolerability.

What manufacturing and intellectual-property barriers matter?

Manufacturing execution is more important than API exclusivity. A scalable product requires control over:

• Ibuprofen particle-size distribution.
• Acetaminophen bulk density and compression behavior.
• Blend uniformity.
• Bilayer weight variation.
• Tablet hardness and friability.
• Lubrication time.
• Dissolution across stability intervals.
• Moisture exposure.
• Packaging seal integrity.

A sponsor can build defensible know-how around granulation conditions, compression sequencing, coating parameters, and stability controls even where patent protection is limited. Trade-secret protection is particularly relevant for process settings and flavor systems.

Geographic coverage should be evaluated separately. U.S. OTC status does not establish approval in the European Union, Canada, Japan, or emerging markets. Each jurisdiction may apply different rules to fixed-dose combinations, labeling, pediatric use, and generic substitution.

What commercial opportunities exist?

The strongest opportunities are segmented rather than mass-market replacement of Advil or Tylenol.

High-potential segments

1. Pediatric liquid or chewable products with improved taste and dose flexibility.
2. Lower-dose products intended to reduce exposure to either active ingredient.
3. Rapid-onset products supported by dissolution and pharmacokinetic data.
4. Modified-release products for longer-duration pain coverage.
5. Private-label products for retailers and pharmacy chains.
6. Travel, workplace, and sports-medicine packs.
7. Hospital and institutional products with standardized dosing.
8. Co-packaged systems that separate the two actives until use.
9. Products targeting patients who cannot swallow conventional tablets.
10. Global products adapted to local OTC rules and dosing conventions.

Revenue exposure

Revenue is most vulnerable in the standard immediate-release segment, where price comparison is easy and switching costs are low. Brand value, packaging, retail placement, advertising, and trust in dosing accuracy can preserve premium pricing, but generic erosion remains likely once comparable products are widely distributed.

A differentiated delivery system can increase gross margin, but it also raises development, testing, manufacturing, and regulatory costs. The best return profile is likely to come from a formulation that solves a specific use problem without requiring a large clinical program.

Key Takeaways

• Acetaminophen-ibuprofen is a mature combination with low API exclusivity.
• Advil Dual Action is the principal U.S. branded reference product, combining acetaminophen 250 mg with ibuprofen 125 mg.
• Bilayer tablets offer the strongest conventional formulation platform.
• Liquid, chewable, orally disintegrating, and modified-release formats provide higher differentiation.
• Patent value depends on measurable formulation or pharmacokinetic advantages.
• Standard immediate-release tablets face substantial generic and private-label risk.
• OTC monograph status, NDA requirements, Orange Book listings, and patent certifications must be assessed product by product.
• Manufacturing know-how, taste masking, dissolution control, packaging, and retail execution are major commercial barriers.
• The highest-value opportunities are differentiated delivery systems and targeted channels rather than undifferentiated tablets.

FAQs

Can acetaminophen and ibuprofen be combined in one tablet?

Yes. Fixed-dose products combine the two active ingredients in a single tablet or caplet. The formulation must control dose uniformity, dissolution, stability, and labeling requirements for both ingredients.

Is a bilayer acetaminophen-ibuprofen tablet patentable?

Potentially, but a bilayer structure alone may be insufficient. Stronger claims require a novel structure, manufacturing process, dissolution profile, stability benefit, or clinically relevant performance improvement.

Can a generic manufacturer copy Advil Dual Action?

A generic manufacturer may be able to develop a comparable product, subject to FDA regulatory requirements, Orange Book listings, patent certifications, labeling restrictions, and any enforceable formulation or method-of-use patents.

Are acetaminophen-ibuprofen liquids commercially attractive?

Yes. Liquid products have higher technical barriers because of solubility, suspension, taste, preservative, and dose-uniformity requirements. Those barriers can support premium pricing and pediatric or institutional positioning.

What is the best excipient for improving ibuprofen dissolution?

No single excipient is universally optimal. Surfactants, wetting agents, particle-size reduction, copovidone, disintegrants, and hydrophilic carriers can improve performance. The selected system must be validated through dissolution, stability, manufacturability, and sensory testing.

References

1. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: The Orange Book. FDA.

2. U.S. Food and Drug Administration. (2023). Over-the-counter monograph M013: Internal analgesic, antipyretic, and antirheumatic drug products. FDA.

3. U.S. Food and Drug Administration. (2015). Guidance for industry: ANDAs for certain highly purified synthetic peptides. FDA.

4. Haleon. (2024). Advil Dual Action product labeling. Haleon Consumer Healthcare.

5. U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs database. FDA.

6. United States Pharmacopeia. (2024). United States Pharmacopeia and National Formulary. U.S. Pharmacopeial Convention.